Is Long Term Avexitide Supply Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)?

• Amylyx Pharmaceuticals disclosed past agreements with Bachem Americas and a term sheet with Polypeptide Group to supply avexitide from 2028, including minimum annual purchase quantities, volume based pricing and a US$30 million upfront capacity reservation fee.
• The long term, non exclusive manufacturing setup and binding supply forecasts indicate that Amylyx is committing real cash and operational planning to the potential commercialization of avexitide, while maintaining flexibility with alternate suppliers.
• The focus now shifts to how this long term avexitide supply build out could reshape Amylyx Pharmaceuticals’ investment narrative and risk profile.

Compare Amylyx Pharmaceuticals’ long term manufacturing push with other healthcare developers securing future capacity by scanning our curated list of solid balance sheet and fundamentals (23 results) for potential parallels and contrasts.

Amylyx Pharmaceuticals Investment Narrative Recap

To own Amylyx Pharmaceuticals, you need to believe avexitide can clear the LUCIDITY Phase III hurdle and then convert PBH awareness into real prescribing and payer coverage. The new supply deals mainly sit behind that catalyst. They improve readiness for a possible 2027 launch but do not change the fact that top line LUCIDITY data in Q3 2026 still drives the story.

The biggest operational risk remains binary. If LUCIDITY misses, Amylyx loses its lead PBH asset and earliest potential revenue stream while still carrying R&D and commercial build out. Over the longer term, minimum purchase commitments and a US$30 million capacity fee add fixed obligations that matter more if uptake or pricing land below expectations.

The most relevant announcement for this capacity build is Amylyx Pharmaceuticals presenting at the Morgan Stanley Global Healthcare Conference on 15 September 2026. That forum gives management a chance to explain how avexitide manufacturing, NDA preparation and commercial planning fit together, with LUCIDITY data timing front of mind for investors.

Conference appearances also put execution questions in focus. You can watch for detail on how Amylyx prioritizes spend across avexitide, AMX0318 and its neurodegeneration programs, given a reported cash balance of US$317 million funding operations into 2028. The more clearly management links this supply build to concrete regulatory and launch milestones, the easier it is to judge risk versus potential reward.

Amylyx Pharmaceuticals’ current analyst narrative points to forecast revenue of US$343.4 million and expected earnings of US$86.8 million by 2029, based on a move from an earnings loss of US$152.1 million today. This implies a very large swing in profitability, with earnings rising by about US$238.9 million if that consensus plays out.

Uncover why Amylyx Pharmaceuticals’ fair value indicates a 31% potential upside to its current price, which could narrow quickly.

Exploring Other Perspectives

For a different angle, focus on how optimistic analysts treat the avexitide launch itself as the key catalyst. They were already modeling US$518.3 million of revenue and US$75.4 million of earnings by 2029 for Amylyx Pharmaceuticals before this supply news. That is far more upbeat than consensus. Use that gap as a prompt to explore multiple viewpoints that may shift as these long term capacity deals sink in.

Explore another Amylyx Pharmaceuticals fair value estimate, including one that suggests as much as 521% upside from the current price!

Form Your Own Verdict

Don’t just follow the ticker. Dig into the data and build a conviction that’s truly your own.

Looking for more investment ideas beyond Amylyx Pharmaceuticals?

If you want to stress test your view on Amylyx Pharmaceuticals and broaden your watchlist, it helps to see how other companies stack up on quality, valuation and risk using the Simply Wall St Screener.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com